Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

After hours: January 31 at 6:05:27 PM EST Loading Chart for SYRE ...

while also executing on our complex generics and biosimilars business, supported by new product launches. We are also excited to advance to Phase 3 trials for our duvakitug (anti-TL1A) asset." ...

Duvakitug has high potency in vitro, has high selectivity for the DR3 receptor, has low anti-drug antibodies. It shows a rapid, profound, and prolonged suppression of the free TL1A levels in the ...